At Close: 4:00 PM
MannKind Stock Price Graph
MannKind Stock Price Today
MannKind Corporation (MNKD) stock declined over -3.31% intraday to trade at $3.5 a share on NASDAQ. The stock opened with a gain of 14.49% at $4.03 and touched an intraday high of $4.06, falling -0.57% against the last close of $3.52. The MannKind Corporation in stock market went to a low of $3.89 during the session.
MannKind Stock Snapshot
Number of Shares
Cash Flow per Share
Free Float in %
MannKind Stock Price History Chart
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
Frequently Asked Questions
What is the current MannKind Corporation (MNKD) stock price?
MannKind Corporation (NASDAQ: MNKD) stock price is $3.50 in the last trading session. During the trading session, MNKD stock reached the peak price of $4.06 while $3.89 was the lowest point it dropped to. The percentage change in MNKD stock occurred in the recent session was -3.31% while the dollar amount for the price change in MNKD stock was -$0.12.
MNKD's industry and sector of operation?
The NASDAQ listed MNKD is part of Biotechnology industry that operates in the broader Healthcare sector. MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes.
Who are the executives of MNKD?
Dr. Michael E. Castagna Pharm.D.
Chief Executive Officer & Director
Ms. Rosabel Realica Alinaya
Vice President of Investor Relations & Treasury
Dr. David B. Thomson
Executive Vice President, Gen. Counsel & Sec.
Ms. Lauren M. Sabella
Executive Vice President & Chief Operating Officer
How MNKD did perform over past 52-week?
MNKD's closing price is 0.49% higher than its 52-week low of $3.31 where as its distance from 52-week high of $5.75 is -0.32%.
How many employees does MNKD have?
Number of MNKD employees currently stands at N/A. MNKD operates from 30930 Russell Ranch Road, Westlake Village, CA 91362, US.
Link for MNKD official website?
Official Website of MNKD is: https://www.mannkindcorp.com
How do I contact MNKD?
How many shares of MNKD are traded daily?
MNKD stock volume for the day was 1885810.00 shares. The average number of MNKD shares traded daily for last 3 months was 2.41 Million.
What is the market cap of MNKD currently?
The market value of MNKD currently stands at $943.5 Million with its latest stock price at $3.50 and N/A of its shares outstanding.